natgillin/translations-raw huggingface dataset:
- om enhver anden medicin mod kræft, du tager eller har taget, idet særlige hensyn skal tages ved behandlinger, som reducerer antallet af hvide blodlegemer, da det kan forårsage yderligere reduktion i antallet af hvide blodlegemer. 
Other medicines and Caelyx Tell your doctor or pharmacist - if you are taking or have recently taken any other medicines, including medicines obtained without a prescription; - about any other cancer treatments you are on or have been taking, as particular care needs to be taken with treatments which reduce the number of white blood cells, as this may cause further reduction in the number of white blood cells.
Dehydrering, hypokaliæmi, hyperkaliæmi, hypomagnesiæmi, hyponatriæmi, hypocalcæmi 
Dehydration, hypokalaemia, hyperkalaemia, hypomagnesaemia, hyponatraemia, hypocalcaemia
Øjne almindelig retinitis 
Eye disorders common retinitis
Ved undersøgelser med gentagne doser hos dyr synes toksicitetsprofilen for Caelyx at svare til den, som er rapporteret efter længere tids infusioner af standard doxorubicinhydrochlorid hos mennesker. 
In repeat dose studies conducted in animals, the toxicity profile of Caelyx appears very similar to that reported in humans who receive long-term infusions of standard doxorubicin hydrochloride.
Folliculitis, svampeinfektion, forkølelsessår (nonherpetisk), infektion i øvre luftveje 
Folliculitis, fungal infection, cold sores (non-herpetic), upper respiratory tract infection
For doser < 90 mg, fortyndes Caelyx i 250 ml, og for doser  90 mg, fortyndes Caelyx i 500 ml. 
For doses < 90 mg, dilute Caelyx in 250 ml, and for doses  90 mg, dilute Caelyx in 500 ml.
Det anbefales, at alle patienter, der behandles med Caelyx, rutinemæssigt og hyppigt får taget elektrokardiogram. 
It is recommended that all patients receiving Caelyx routinely undergo frequent ECG monitoring.
Anvendelse af et andet opløsningsmiddel end glucose 50 mg/ml (5 %) infusionsvæske, opløsning eller tilstedeværelse af bakteriostatiske stoffer som f.eks. benzylalkohol kan forårsage udfældning af Caelyx. 
The use of any diluent other than 5% (50 mg/ml) glucose solution for infusion, or the presence of any bacteriostatic agent such as benzyl alcohol may cause precipitation of Caelyx.
Hvis dette tåles uden reaktion, kan infusionshastigheden fordobles de næste 15 minutter. 
If tolerated without reaction, the infusion rate may then be doubled for the next 15 minutes.
Da det aktive stof doxorubicinhydrochlorid i Caelyx kan være skadeligt for børn der ammes, skal kvinder ophøre med amning før start af behandling med Caelyx. 
Because doxorubicin hydrochloride may be harmful to nursing infants, women must discontinue breast-feeding before starting treatment with Caelyx.
Dosisjustering hos patienter med AIDS-KS er beskrevet under pkt. 
Dose modification in patients with AIDS-KS is addressed in section 4.8.
Uge efter forudgående Caelyx-dosis 
Week after prior Caelyx dose
Der er i yderst sjældne tilfælde rapporteret om sekundær oral cancer hos patienter efter langvarig (over et år) eksponering for Caelyx og hos patienter, der fik en kumulativ dosis Caelyx over 720 mg/m2. 
Very rare cases of secondary oral cancer have been reported in patients with long-term (more than one year) exposure to Caelyx or those receiving a cumulative Caelyx dose greater than 720 mg/m2.
For almindelige bivirkninger, der krævede ændringer i dosis eller afbrydelse henvises til pkt. 
For common adverse events which required dose modification or discontinuation see section 4.8.
Blod og lymfesystem meget almindelig neutropeni, anæmi, leukopeni almindelig trombocytopeni 
Blood and lymphatic system disorders very common neutropaenia, anaemia, leukopaenia common thrombocytopaenia
PPE blev rapporteret hos 16 % af patienterne med myelomatose, der blev behandlet med Caelyx og bortezomib kombinationsbehandling. 
PPE was reported in 16% of multiple myeloma patients treated with Caelyx plus bortezomib combination therapy.
Hvis du behandles for brystcancer eller ovariecancer, vil Caelyx blive givet i en dosis på 50 mg per kvadratmeter af din legemsoverfladeareal (baseret på din højde og vægt). 
If you are being treated for breast cancer or ovarian cancer, Caelyx will be administered at a dose of 50 mg per square metre of your body surface area (based on your height and weight).
Anvend ikke præparatet ved tegn på bundfald eller anden partikeldannelse. 
Do not use material that shows evidence of precipitation or any other particulate matter.
Vaskulære sygdomme ikke almindelig venøs tromboemboli inklusive tromboflebitis, venøs trombose og lungeemboli 
Vascular disorders uncommon venous thromboembolism, including thrombophlebitis, venous thrombosis and pulmonary embolism
Kvalme og opkastning blev rapporteret hyppigere i gruppen, der fik kombinationsbehandling (40 % og 28 %) end i monoterapi-gruppen (32 % og 15 %) og var fortrinsvist af grad 1 og 2 sværhedsgrad. 
Nausea and vomiting were reported more frequently in the combination therapy group (40% and 28%) than in the monotherapy group (32% and 15%) and were mostly grade 1 and 2 in severity.
De kan finde yderligere oplysninger om Caelyx på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu. 
Detailed information on this medicine is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/.
Tør hud, misfarvning af huden 
Dry skin, skin discolouration
Caelyx indeholder - Aktivt stof: doxorubicinhydrochlorid. 
What Caelyx contains - The active substance is doxorubicin hydrochloride.
Splenektomerede patienter med AIDS-relateret KS Da der ikke er erfaring med Caelyx hos patienter, som har fået foretaget splenektomi, anbefales behandling med Caelyx ikke. 
As there is no experience with Caelyx in patients who have had splenectomy, treatment with Caelyx is not recommended.
Hovedpine, svimmelhed, neuropati, hypertoni 
Headache, dizziness, neuropathy, hypertonia
Hos patienter med AIDS-KS var infusionsrelaterede reaktioner karakteriserede ved rødme, kortåndethed, ansigtsødem, hovedpine, kulderysten, rygsmerter, sammensnørende fornemmelse over thorax og hals og/eller hypotension og kan forventes med en hyppighed på 5 % til 10 %. 
In patients with AIDS-KS, infusion-associated reactions, were characterised by flushing, shortness of breath, facial oedema, headache, chills, back pain, tightness in the chest and throat and/or hypotension and can be expected at the rate of 5% to 10%.
Hvis du behandles for Kaposis sarkom, vil Caelyx blive givet i en dosis på 20 mg per kvadratmeter af din legemsoverfladeareal (baseret på din højde og vægt). 
If you are being treated for Kaposi'sarcoma, Caelyx will be administered at a dose of 20 mg per square metre of your body surface area (based on your height and weight).
Det anbefales, at Caelyx-infusionsslangen forbindes via en sideport til en intravenøs infusion med glucose 50 mg/ml (5 %) for at opnå yderligere fortynding og mindske risikoen for trombose og ekstravasation. 
It is recommended that the Caelyx infusion line be connected through the side port of an intravenous infusion of 5% (50 mg/ml) glucose to achieve further dilution and minimise the risk of thrombosis and extravasation.
Under infusion af Caelyx kan følgende reaktioner forekomme: Rødme i ansigtet, åndenød, hovedpine, kulderystelser, rygsmerter, sammensnøring af brystet og/eller halsen, ondt i halsen, lavt blodtryk eller stigning i blodtrykket, hurtige hjerteslag, opsvulmen af ansigtet, feber, svimmelhed, kvalme, dårlig fordøjelse, kløe, udslæt og svedtendens. 
During the infusion of Caelyx, the following reactions may occur: flushing of the face, shortness of breath, headache, chills, back pain, tightness in the chest and/or throat, sore throat, low or increase in blood pressure, rapid heart beat, puffing of the face, fever, dizziness, nausea, indigestion, itching, rash and sweating.
Grad 2 (smertefuldt erytem, ødem eller sår, men kan spise) 
Grade 2 (painful erythema, oedema, or ulcers, but can eat)
Caelyx kan fås som hætteglas i en enkeltpakning eller pakninger med ti hætteglas. 
Caelyx is available in glass vials as a single pack or packs of ten vials.
Træthed, svaghed, smerte 
Fatigue, weakness, pain
Alvorlige og nogle gange livstruende infusionsreaktioner, som er karakteriseret ved allergilignende eller anafylaktoid-lignende reaktioner med symptomer omfattende astma, rødme, urticaria-udslæt, brystsmerte, feber, hypertension, takykardi, kløe, svedtendens, kortåndethed, ansigtsødem, kulderystelser, rygsmerte, sammensnørende fornemmelse over thorax og hals og/eller hypotension, kan forekomme inden for minutter efter start af infusionen af Caelyx. 
Serious and sometimes life-threatening infusion reactions, which are characterised by allergic-like or anaphylactoid-like reactions, with symptoms including asthma, flushing, urticarial rash, chest pain, fever, hypertension, tachycardia, pruritus, sweating, shortness of breath, facial oedema, chills, back pain, tightness in the chest and throat and/or hypotension may occur within minutes of starting the infusion of Caelyx.
I meget sjældne tilfælde har kramper også været set i forbindelse med infusionsrelaterede reaktioner (se pkt. 
Very rarely, convulsions also have been observed in relation to infusion reactions (see section 4.8).
Caelyx 2 mg/ml koncentrat til infusionsvæske, opløsning 
Caelyx 2 mg/ml concentrate for solution for infusion
Da en vurdering af post-marketing sikkerhedsdatabasen for Caelyx hos patienter ikke har tydet på en signifikant tilbøjelighed til nefrotoksicitet ved Caelyx, vil disse fund hos aber måske ikke have relevans for vurdering af patientrisiko. 
Caelyx in patients has not suggested a significant nephrotoxicity liability of Caelyx, these findings in monkeys may not have relevance to patient risk assessment.
Caelyx skal håndteres og bortskaffes i henhold til retningslinjerne for håndtering af andre lægemidler mod kræft. 
Caelyx must be handled and disposed of in a manner consistent with that of other anticancer medicinal products.
Caelyx 2 mg/ml koncentrat til infusionsvæske, opløsning pegyleret liposomal doxorubicinhydrochlorid 
Caelyx 2 mg/ml concentrate for solution for infusion Pegylated liposomal doxorubicin hydrochloride
Forekomsten af grad 3 og grad 4 neutropeni var højere hos gruppen, der var i kombinationsbehandling end i monoterapi-gruppen (28 % vs. 14 %). 
The incidence of grade 3 and 4 neutropaenia was higher in the combination therapy group than in the monotherapy group (28% vs. 14%).
I toksikologistudier hos hunde med gentagne doser iagttog man et akut respons efter indgift af pegylerede liposomer (placebo), der karakteriseredes af hypotension, blege slimhinder, spytafsondring, emesis og perioder med hyperaktivitet fulgt af hypoaktivitet og letargi. 
During repeat dose toxicology studies in dogs, an acute response characterised by hypotension, pale mucous membranes, salivation, emesis and periods of hyperactivity followed by hypoactivity and lethargy was observed following administration of pegylated liposomes (placebo).
Tør hud, misfarvning af huden, unormal pigmentering, erytem 
Dry skin, skin discolouration, pigmentation abnormal, erythema
Overlevelsen ved 1, 2 og 3 år var henholdsvis 74,1 %, 51,2 % og 28,4 % for Caelyx sammenlignet med henholdsvis 66,2 %, 31,0 % og 17,5 % for topotecan. 
The survival rates at 1, 2 and 3 years were 74.1%, 51.2% and 28.4% respectively on Caelyx, compared to 66.2%, 31.0% and 17.5% on topotecan.
Neuropatisk smerte eller perifer neuropati 
Neuropathic pain or peripheral neuropathy
Pegylerede liposomer indeholder overfladeforædlede segmenter af den hydrofile polymer, methoxypolyethylenglykol (MPEG). 
Pegylated liposomes contain surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol (MPEG).
Der var en forbedring i total overlevelse (OS) for Caelyx-behandlede patienter i forhold til topotecan-behandlede patienter indikeret ved en hazard ratio (HR) på 1,216 (95 % CI: 1,000; 1,478), p=0,050. 
There was a benefit in overall survival (OS) for Caelyx-treated patients over topotecan-treated patients as indicated by a hazard ratio (HR) of 1.216 (95% CI: 1.000; 1.478), p=0.050.
Forekomsten af grad 3 og grad 4 trombocytopeni var højere hos gruppen, der var i kombinationsbehandling end i monoterapi-gruppen (22 % vs. 14 %). 
The incidence of grade 3 and 4 thrombocytopaenia was higher in the combination therapy group than in the monotherapy group (22% vs. 14%).
Tabel 4 nedenfor viser det skema, der er fulgt for andre doseringsændringer i den kliniske undersøgelse af kombinationsbehandling med Caelyx og bortezomib af patienter med myelomatose. 
Table 4, below provides the schedule followed for other dose modifications in the clinical trial in the treatment of patients with multiple myeloma receiving Caelyx and bortezomib combination therapy.
Ovariecancer Grad 3/4 n=512 
Ovarian cancer Grades 3/4 n=512
Træk patienten ud af behandlingen 
Withdraw patient
Grad 3 (smertefuldt erytem, ødem eller sår, men kan ikke spise) 
Grade 3 (painful erythema, edema, or ulcers, but cannot eat)
På grund af forskelle i farmakokinetiske egenskaber og dosering må Caelyx ikke ombyttes med andre formuleringer af doxorubicinhydrochlorid. 
Given the difference in pharmacokinetic profiles and dosing schedules, Caelyx should not be used interchangeably with other formulations of doxorubicin hydrochloride.
Se tabel 7 for bivirkninger rapporteret hos ≥ 5 % af de patienter, der blev behandlet med Caelyx og bortezomib kombinationsbehandling. 
See Table 7 for adverse effects reported in ≥ 5% patients treated with combination therapy of Caelyx plus bortezomib.
Nervesystemet almindelig svimmelhed ikke almindelig paræstesi 
Nervous system disorders common dizziness uncommon paresthesia
Overlevelsen ved 1, 2 og 3 år var henholdsvis 41,5 %, 21,1 % og 13,8 % for Caelyx sammenlignet med henholdsvis 43,2 %, 17,2 % og 9,5 % for topotecan. 
The survival rates at 1, 2 and 3 years were 41.5%, 21.1% and 13.8% respectively on Caelyx, compared to 43.2%, 17.2% and 9.5% on topotecan.
Caelyx, en liposom-formulering, er doxorubicinhydrochlorid indkapslet i liposomer med overfladebundet methoxypolyethylenglycol (MPEG). 
Caelyx, a liposome formulation, is doxorubicin hydrochloride encapsulated in liposomes with surface-bound methoxypolyethylene glycol (MPEG).
-(2-[1,2-distearoyl-sn-glycero(3)phosphooxy]ethylcarbamoyl)--methoxypoly(oxyethylen)40 natriumsalt (MPEG-DSPE) helhydrogeneret sojafosfatidylcholin (HSPC) kolesterol ammoniumsulfat saccharose histidin vand til injektionsvæsker saltsyre (til justering af pH) natriumhydroxid (til justering af pH). 
-(2-[1,2-distearoyl-sn-glycero(3)phosphooxy]ethylcarbamoyl)--methoxypoly(oxyethylen)-40 sodium salt (MPEG-DSPE) fully hydrogenated soy phosphatidylcholine (HSPC) cholesterol ammonium sulphate sucrose histidine water for injections hydrochloric acid (for pH-adjustment) sodium hydroxide (for pH-adjustment)
Det kan mildne den lokale reaktion, hvis man holder is mod ekstravasationsstedet i omkring 30 minutter. 
The application of ice over the site of extravasation for approximately 30 minutes may be helpful in alleviating the local reaction.
* palmorplantar erytrodysæstesi (hånd-fod syndrom) 
* palmar-plantar erythrodysesthesia (Hand-foot syndrome).
Brystcancerpatienter 
Breast cancer patients
AIDS-relateret KS Caelyx indgives intravenøst i en dosis på 20 mg/m2 hver anden til tredje uge. 
AIDS-related KS Caelyx is administered intravenously at 20 mg/m2 every two-to-three weeks.
Caelyx udviser enestående farmakokinetiske egenskaber og må ikke ombyttes med andre formuleringer af doxorubicinhydrochlorid. 
Caelyx exhibits unique pharmacokinetic properties and must not be used interchangeably with other formulations of doxorubicin hydrochloride.
Hovedpine, perifer sensorisk neuropati, parestesi, svimmelhed 
Headache, peripheral sensory neuropathy, paraesthesia, dizziness
I den pivotale fase III undersøgelse over for doxorubicin opfyldte 58/509 (11,4 %) randomiserede patienter (10 behandlet med Caelyx i en dosis på 50 mg/m2/hver 4. uge mod 48 behandlet med doxorubicin i en dosis på 60 mg/m2/hver 3. uge) de protokoldefinerede kriterier for kardiel toksicitet under behandling og/eller opfølgning. 
In the pivotal phase III trial versus doxorubicin, 58/509 (11.4%) randomised subjects (10 treated with Caelyx at a dose of 50 mg/m2/every 4 weeks versus 48 treated with doxorubicin at a dose of
Behandlingsrelaterede bivirkninger, der er rapporteret ved kliniske undersøgelser af myelomatose (Caelyx 30 mg/m2 i kombination med bortezomib hver 3. uge) efter sværhedsgrad, systemorganklasser i henhold til MedDRA-databasen og standardterminologi Meget almindelig (≥ 1/10); Almindelig (≥ 1/100 til < 1/10); Ikke almindelig (≥ 1/1.000 til 
Treatment related undesirable effects reported in multiple myeloma clinical trial (Caelyx 30 mg/m2 in combination with bortezomib every 3 weeks) by severity, MedDRA system organ class and preferred term Very common (≥ 1/10); Common (≥ 1/100, < 1/10); Uncommon (≥ 1/1,000, < 1/100)
* Palmoplantar erytrodysæstesi (hånd-fod syndrom). 
* Palmar-plantar erythrodysesthesia (Hand-foot syndrome).
Brystsmerter 
Breast pain
Så meget Caelyx vil du få 
How much Caelyx is given
Caelyx må ikke indgives intramuskulært eller subkutant. 
Caelyx must not be given by the intramuscular or subcutaneous route.
Luftveje, thorax og mediastinum almindelige dyspnø 
Respiratory, thoracic and mediastinal disorders common dyspnoea
Der er indberettet tilfælde af sekundær oral cancer hos patienter efter langvarig (over et år) eksponering for Caelyx og hos patienter, der fik en kumulativ dosis Caelyx over 720 mg/m2 (se pkt. 
Cases of secondary oral cancer have been reported in patients with long-term (more than one year) exposure to Caelyx or those receiving a cumulative Caelyx dose greater than 720 mg/m2 (see section 4.4).
Overlevelsen ved 1, 2 og 3 år var henholdsvis 56,3 %, 34,7 % og 20,2 % for Caelyx sammenlignet med henholdsvis 54,0 %, 23,6 % og 13,2 % for topotecan. 
The survival rates at 1, 2 and 3 years were 56.3%, 34.7% and 20.2% respectively on Caelyx, compared to 54.0%, 23.6% and 13.2% on topotecan.
Det anbefales, at Caelyx-infusionsslangen forbindes via en sideport til en intravenøs infusion med glucose 50 mg/ml (5 %). 
It is recommended that the Caelyx infusion line be connected through the side port of an intravenous infusion of 5% (50 mg/ml) glucose.
I kontrollerede kliniske undersøgelser med patienter med AIDS-KS var opportunistiske infektioner tilsyneladende mere hyppige under behandling med Caelyx sammenlignet med bleomycin/vincristin behandling. 
In controlled clinical studies in patients with AIDS-KS against a bleomycin/vincristine regimen, opportunistic infections were apparently more frequent during treatment with Caelyx.
I modsætning til erfaringen med patienter med AIDS-KS var risikoen for infektioner imidlertid betydelig mindre i Caelyx-behandlede patienter sammenlignet med patienter i standardbehandling for fremskreden ovariecancer (topotecan). 
However, in contrast to the experience with patients with AIDS-KS, when Caelyx was compared to a standard treatment for advanced ovarian cancer (topotecan), the risk of infections was substantially lower in the Caelyx-treated patients.
Neutropeni, trombocytopeni 
Neutropaenia, thrombocytopaenia
I denne samlede analyse af 4.231 patienter, som fik Caelyx er ventrikulær arytmi, palpitationer, hjertesvigt, hjertestop, højresidig grenblok og reduceret uddrivningsfraktion (ejection fraction) rapporteret med hyppigheden ikke almindelig og atrioventrikulært blok, cyanose og ledningsforstyrrelse rapporteret med hyppigheden sjældne. 
In this pooled analysis of 4,231 patients receiving Caelyx, ventricular arrythmia, palpitations, cardiac failure, cardiac arrest, bundle branch block right, and ejection fraction decreased were reported uncommonly, and atrioventricular block, cyanosis, and conduction disorder were reported rarely.
Genopblussen af hudreaktion forårsaget af tidligere stråleterapi er i sjældne tilfælde set ved Caelyxbehandling. 
Recall of skin reaction due to prior radiotherapy has rarely occurred with Caelyx administration.
Farmakokinetikken for Caelyx bestemt hos 18 patienter med brystcarcinom svarede til farmakokinetikken bestemt i den større population på 120 patienter med forskellige cancerformer. 
The pharmacokinetics of Caelyx determined in 18 patients with breast carcinoma were similar to the pharmacokinetics determined in the larger population of 120 patients with various cancers.
Gennemsnitlig intrinsic clearance var 0,016 l/time/m2 (interval fra 0,008 - 0,027 l/time/m gennemsnitlig centrale fordelingsvolumen var 1,46 l/m 2 (interval fra 1,10 - 1,64 l/m 2). 
The mean intrinsic clearance was 0.016 l/h/m2 (range 0.008-0.027 l/h/m2), the mean central volume of distribution was 1.46 l/m 2 (range 1.10-1.64 l/m 2).
EU/1/96/011/003 (1 hætteglas) EU/1/96/011/004 (10 hætteglas) 
EU/1/96/011/003 (1 vial) EU/1/96/011/004 (10 vials)
Hypotension, ortostatisk hypotension, ansigtsrødme, hypertension, flebitis 
Hypotension, orthostatic hypotension, flushing, hypertension, phlebitis
Anvend kun Caelyx til patienter med behandlingskrævende kardiovaskulær sygdom, hvis fordelen opvejer risikoen for patienten. 
In patients with cardiac disease requiring treatment, administer Caelyx only when the benefit outweighs the risk to the patient.
Median-TTP var 6,5 måneder for patienterne, der fik bortezomib-monoterapi, sammenlignet med 9,3 måneder for de patienter, der fik Caelyx plus bortezomib-kombinationsbehandling. 
The median TTP was 6.5 months for the bortezomib monotherapy patients compared with 9.3 months for the Caelyx plus bortezomib combination therapy patients.
Caelyx-dosen fortyndes i 250 ml glucose 50 mg/ml (5 %) infusionsvæske, opløsning og indgives som intravenøs infusion over 30 minutter. 
The dose of Caelyx is diluted in 250 ml 5% (50 mg/ml) glucose solution for infusion and administered by intravenous infusion over 30 minutes.
Median-TTP var 6,9 måneder for patienterne, der fik bortezomib-monoterapi, sammenlignet med 8,9 måneder for patienterne, der fik kombinationsbehandling med Caelyx plus bortezomib. 
The median TTP was 6.9 months for the bortezomib monotherapy patients compared with 8.9 months for the Caelyx plus bortezomib combination therapy patients.
EU/1/96/011/001 (1 hætteglas) EU/1/96/011/002 (10 hætteglas) 
EU/1/96/011/001 (1 vial) EU/1/96/011/002 (10 vials)
Sådan skal du bruge Caelyx 
How to use Caelyx
Pyridoxin (vitamin B6): - vitamin B6 kan fås uden recept. 
Pyridoxine (Vitamin B6): - vitamin B6 is available without prescription; - take 50-150 mg daily beginning at the first signs of redness or tingling.
JUSTERING Grad 1 1.500 - 1.900 75.000 - 150.000 Genoptag behandling uden dosisreduktion. 
75,000 - 150,000 Resume treatment with no dose reduction.
Hos 100 af 929 patienter (10,8 %) med massive tumorer blev infusionsrelaterede reaktioner beskrevet under behandling med Caelyx, karakteriseret ved følgende Costart termer: allergisk reaktion, anafylaktoid reaktion, astma, ansigtsødem, hypotension, vasodilatation, urticaria, rygsmerter, 
100 out of 929 patients (10.8%) with solid tumours were described as having an infusion-associated reaction during treatment with Caelyx as defined by the following Costart terms: allergic reaction, anaphylactoid reaction, asthma, face oedema, hypotension, vasodilatation, urticaria, back pain, chest pain, chills, fever, hypertension, tachycardia, dyspepsia, nausea, dizziness, dyspnoea, pharyngitis, rash, pruritus, sweating, injection site reaction and medicinal product interaction.